Thermo Fisher Scientific Inc. (TMO), on Monday, announced that it has signed a definitive agreement to sell its microbiology business to Astorg.
The transaction is approximately $1.075 billion, consisting of cash and a $50 million seller note.
The deal is expected to close in the second half of 2026.
The company said the microbiology business provides antimicrobial susceptibility testing and culture media solutions and generated $645 million in revenue in 2025.
Thermo Fisher said the deal is expected to be dilutive to adjusted earnings per share by $0.15 in the first full year following the close.
The company said it will provide further details on the expected impact on its 2026 outlook during its second-quarter earnings call.
In the pre-market trading, Thermo Fisher Scientific is 0.15% lesser at $469 on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.